| 
MEDIPOST and Dong-A Pharmaceutical Co., Ltd., the No 1. pharmaceutical company in Korea, have signed an exclusive marketing agreement for CARTISTEM®, a knee articular cartilage regenerative hUCB-MSCs drug, for the territory of Korea.
MEDIPOST and Dong-A Pharmaceutical Co., Ltd. plan to collaborate for a post-marketing, long-term follow up study of clinical trial phase I to III while expanding the applicability of CARTISTEM®.
In return, MEDIPOST receives the largest milestone payments ever recorded in Korea with a running royalty according to sales performance.
|
